Houstonians are going to be the first in the country to try out a new Nissan subscription service. Photo courtesy of Nissan North America

Volvo and Porsche are already doing it. Now, Nissan is getting in on the vehicle subscription service model with a new program called Nissan Switch. The service will debut in Houston.

"Nissan Switch is another way that Nissan is testing alternatives to the notion of traditional mobility, without long-term financial commitments for our customers," said Andrew Tavi, vice president, Legal, External Affairs and Business Development, Nissan North America, Inc. "This program provides more choice, convenience, and flexibility. For those who want a sedan during the week and an SUV or sports car, like the GTR, on the weekends, Nissan Switch provides the solution."

By signing up for the Nissan Switch program, subcribers can test models including the Nissan Leaf Plus, Titan, and GT-R. Nissan has recently redesigned many of the vehicles in their lineup including the Versa, Sentra, and Altima. The Frontier got a new engine for the 2020 model year and Murano, Maxima, and Titan have gotten significant updates in the past 18 months.

The program works similar to how on-demand media programming works. The price tier of the service subscribed to dictates the vehicles that can be switched out. There is no long-term contract or commitment.

For $699 per month, subscribers have access to the Altima sedan, Rogue and Pathfinder SUVs, and Frontier truck. Spending $899 per month allows for testing of the Leaf Plus electric vehicle, Maxima sedan, Murano and Armada SUVs, Titan truck, and 370Z sports car. Those wishing to test out the GT-R must elect for the $899 per month Premium service level and pay an additional $100 per day with seven-day consecutive maximum use.

Subscribers won't be driving just rental car spec base models. Each vehicle will be featured in a well-equipped trim level, some with Nissan's ProPilot Assist driver-assist technology that has features including lane centering, lane keeping, and blind spot warning.

After a $495 membership activation fee, the monthly subscription includes the vehicle (unlimited switches, as often as a new vehicle each day), delivery, cleaning, insurance, roadside assistance, and regular maintenance.

------

This article originally ran on AutomotiveMap.

Lindsey Rose King created a seasonal home goods box that shows consumers how to enjoy each item. Courtesy of Mostess

Houston-based subscription box startup plans expansion and new subscriber features

Hostess with the Mostess

A few years ago, Lindsey Rose King offered to host her friend's engagement party, and she realized she had no clue where to start. There weren't any real resources out there for her to seek out.

King created Mostess, a seasonally curated home goods subscription box aiming to make it easier to host friends and family into their homes. The company was founded in January of 2017.

"I came up with the idea out of a need," says King, founder and lead curator, "it's hard to casually invite people into your house."

Almost two years later, King has managed to accomplish a lot of her goals, and Mostess has a great retention rate of subscribers with about a 30 percent growth each quarter, King says.

"We have a 5 percent churn rate, so 95 percent of customers have been customers since their first purchase," says King.

Mostess moves to disrupt the retail space by changing how consumers shop for home goods, accessories, and tabletop items. The box presents products in a different setting than consumers are used to seeing in a brick-and-mortar store by combining products from different brands and lines that may not be typically paired.

"Consumers are getting a product because we are referring it and picking it for them," King says. "We're choosing for the consumer, rather than them choosing themselves."

Growing business
In need of more space, the growing company recently moved into a warehouse in the Houston-area in a partnership with Alpha Graphics West Houston to launch its first local fulfillment center.

Currently, Mostess ships to 48 states, and next year, King says she wants to be able to ship to Alaska and Hawaii by July. Since the box has already got some buzz around it in Canada, King says she hope to be able to start her first international shipping there by 2020.

Mostess is in the wrapping up its busiest season; the company just released its winter box, which, along with the autumn box, King says subscribers usually purchase additional boxes for friends and family.

Looking forward to 2019, she's got exciting advancements for her subscribers.

In 2019, Mostess will begin offering slight customizations to each seasonal box and a special evergreen box. Customers will be able to purchase add-on items beginning with the spring box, such as extra candles or accessories in addition to what is offered. The Mostess evergreen boxes will have neutral and classic home accessories and hosting pieces. King says she wants these boxes to be a go-to gift idea or party-hosting asset for everything from a housewarming to an engagement party.

Starting from scratch
King first had the idea for Mostess toward the end of her 10-year stint living in Washington, D.C. Anticipating a move to Houston, King began to research local bloggers and small businesses to build a support system and platform for Mostess prior to the launch.

"In the small business world in Houston, there is the blogging community and there are actual small businesses," says King. "Both are very active and both very open to chatting about how to make business work between both of you."

King tells InnovationMap that Houston is an ideal city for an entrepreneur, offering a collaborative community of friendly, laid back, and hard-working small business owners.

King shares that she launched Mostess without any outside investment, using only her personal funds to get the product off the ground and relied on her friends and family as a test market. From there, she sought feedback from every single customer and potential customer, collected data, and tweaked details leading up to the launch.

"There was not a home goods subscription box on the market," says King, "I didn't have something to model after."

Elegant items shipped to your door

Paige Baker/Mostess

Mostess memberships begin at $120 per seasonal box.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.